RA

Evoke Consulting Extends Support to USMC M&RA Service Treatment Records Program with New Contract Award

Retrieved on: 
Thursday, January 20, 2022 - 3:00pm

Jim Loreto, Evoke's Managing Partner, stated, "The STR Program ensures service members receive timely and accurate health services following their transition from active duty.

Key Points: 
  • Jim Loreto, Evoke's Managing Partner, stated, "The STR Program ensures service members receive timely and accurate health services following their transition from active duty.
  • Evoke is honored to continue supporting Marine Veterans as they receive benefits earned for service to our Nation."
  • Evoke Managing Partner, Greg Blaisdell, added, "Evoke is proud of our STR team's demonstrated commitment to the Marine Corps.
  • Evoke Research and Consulting, LLC provides professional services and technology support in management, organizational improvement, and technology and engineering services.

MEET BEZZY, HEALTHLINE MEDIA'S NEW SUITE OF COMMUNITIES FOR PEOPLE LIVING WITH CHRONIC HEALTH CONDITIONS

Retrieved on: 
Tuesday, January 18, 2022 - 1:01pm

SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ --Today, Healthline Mediais launching a suite of seven health condition communities through its new brand, Bezzy .

Key Points: 
  • SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ --Today, Healthline Mediais launching a suite of seven health condition communities through its new brand, Bezzy .
  • Bezzy creates a supportive, moderated experience where people with chronic conditions feel seen, valued, and understood.
  • Bezzy exists toempower belonging and aims to cultivate a supportive community for people navigating chronic health conditions.
  • Healthline Media is based in San Francisco and is part of RV Health, a Red Ventures business.

Veriti’s Direct Indexing Technology to Implement Research Affiliates' RAFI Index Strategies

Retrieved on: 
Thursday, January 13, 2022 - 2:08pm

Veriti will utilize its innovative direct indexing technology to implement certain index strategies, including those not currently available in an ETF or mutual fund, of RAs affiliated entity, RAFI Indices .

Key Points: 
  • Veriti will utilize its innovative direct indexing technology to implement certain index strategies, including those not currently available in an ETF or mutual fund, of RAs affiliated entity, RAFI Indices .
  • RAFI Indices is the global index company of Research Affiliates and has more than 50 live strategies worldwide.
  • Research Affiliates constructs, publishes, and licenses these indices based on insights and strategies developed through their award-winning research.
  • This partnership combines Research Affiliates commitment to delivering value via their RAFI Fundamental, RAFI Single Factor, and RAFI Multi-Factor Indices with Veritis tax-efficient implementation technology thereby providing a compelling value proposition for advisors seeking after-tax outperformance for their clients.

Aclaris Therapeutics Provides R&D Update

Retrieved on: 
Tuesday, January 11, 2022 - 9:01pm

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations.

Key Points: 
  • WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations.
  • Aclaris has bolstered its R&D group, including in the areas of clinical, preclinical and discovery, quality, pharmacology, and regulatory.
  • Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options.
  • These documents are available under the SEC Filings page of the Investors section of Aclaris website at www.aclaristx.com.

SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong an

Retrieved on: 
Tuesday, January 11, 2022 - 7:55am

The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".

Key Points: 
  • The Company was also previously awarded the "Listed Company with Most Growth Potential" in the selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies".
  • In addition, SN1011, a key product of the Company, completed its phase I last subject last visit in China in July last year.
  • That reflects the capital market's recognition of the value, management and growth potential of the Company and is a great encouragement to the Company.
  • The selection of the "6th Hong Kong Golden Stocks Awards" was jointly organized by Zhitongcaijing.com, a leading Hong Kong and US stock information platform in China, with RoyalFlush Finance and China Galaxy Securities.

Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection

Retrieved on: 
Sunday, January 9, 2022 - 5:00pm

The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.

Key Points: 
  • The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients.
  • RA patients often try multiple therapies empirically before they find one that lowers their disease activity.
  • There are currently no reliable assays for predicting positive patient response prior to the selection of commonly prescribed biological therapeutic agents.
  • Queen Mary University of London is a world-leading research-intensive university with over 28,000 students representing more than 160 nationalities.

Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Retrieved on: 
Thursday, January 6, 2022 - 1:00pm

Ambagon Therapeutics , a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.

Key Points: 
  • Ambagon Therapeutics , a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.
  • Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital.
  • Several thousand proteins with such intrinsically disordered regions have been identified that interact with the hub protein 14-3-3.
  • Ambagon Therapeutics is a biotechnology company pioneering methods to unlock intrinsically disordered protein targets using small molecules.

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Retrieved on: 
Wednesday, January 5, 2022 - 2:15pm

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled Method of Treating Sarcopenia.

Key Points: 
  • MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled Method of Treating Sarcopenia.
  • The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia.
  • Affecting up to 40% of the elderly, sarcopenia is strictly correlated with physical disability, poor quality of life and death.1
    We all know that aging cannot be prevented.
  • 1 The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses; Mayhew et al.

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Retrieved on: 
Monday, December 27, 2021 - 12:00pm

Pardes Biosciences, Inc., the resulting combined company, will commence trading its shares Monday, December 27th on the Nasdaq Global Market under the symbol PRDS.

Key Points: 
  • Pardes Biosciences, Inc., the resulting combined company, will commence trading its shares Monday, December 27th on the Nasdaq Global Market under the symbol PRDS.
  • Pardes Biosciences management team will continue to be led by Chief Executive Officer Uri A. Lopatin, M.D.
  • We founded Pardes Biosciences in early 2020 to help solve pandemic-sized problems, starting with COVID-19, said Uri A. Lopatin, M.D., Chief Executive Officer of Pardes Biosciences.
  • Pardes Biosciences protease inhibitor, PBI-0451, is currently in Phase I clinical study with early results showing potential for an unboosted oral regimen against COVID-19.

Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis

Retrieved on: 
Thursday, December 23, 2021 - 2:06pm

Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.

Key Points: 
  • Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.
  • Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints.
  • Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
  • For more information on Enzene Biosciences Ltd., please visit www.enzene.com
    For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com